CSI Market
Sign In | Register

Deciphera Pharmaceuticals Inc (DCPH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DCPH Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Deciphera Pharmaceuticals Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-45.08
Depreciation & amortization0.45
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Policy Acquisition Costs0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.92
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation10.17
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Gain Loss On Disposition Of Property-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.88
Increase (Decrease) in Accounts Payable-6.94
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-8.20
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.97
Other Working Capital-0.14
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.37
Discontinued operations0.00
Net Cash flow from Operating Activities-54.59
Investing Activities
Capital Expenditures-0.15
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities83.04
Payments to Acquire Marketable Securities-20.26
Real Estate Investments0.00
Increase (Decrease) of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities62.63
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.52
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments For Repurchase Of Temporary Equity-
Proceeds From Redeemable Shares Issued-
Additional Contribution With Share Exchange-
Borrowing Of Revolving Note-
Proceeds From Repurchase Of Temporary Equity-
Payments For The Extinguishment Of Redeemable Preferred Shares-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.52
Effect of exchange rate on cash flow-0.85
Discontinued operations0.00
Free Cash Flow-54.73
Total Cash Flow8.57
4 historic quarters locked

Sign in to unlock the full Deciphera Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Deciphera Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001654151-24-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.